Bispecific antibody-mediated cancer therapy with cytokine-induced killer cell

US10556964B2 · kind B2 · utility

Assignee

• Wuhan YZY Biopharma Co., Ltd. · CN

Inventors

• Pengfei Zhou · 流花街道, CN
• Tao Wang · Farmington, US
• Liu Hu · Zhejiang, CN
• Mi Huang · 红钢城街道, CN
• Lijuan Fang · 红钢城街道, CN
• Yang Liu · Columbus, US

Key dates

• Filing date: Jul 21, 2014
• Grant date: Feb 11, 2020
• Expiry date: Jul 21, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided are compositions comprising a MSBODY and a cytotoxic immune cell (e.g., Cytokine-induced killer cell) to form Armed Activated CIK cells (ACCs), wherein the MSBODY comprising a first antigen binding moiety that has specificity for a tumor antigen, and a second antigen binding moiety that binds to the cell. Provided are also methods preparing a composition comprising a MSBODY and a cytotoxic immune cell, and methods for treating patients with CIK cells armed with bispecific antibodies.